Generic (Mobocertinib) MOBODX

Inquire / Price
Inquire Now Link

  • Details
  • Description
  • Packaging Size
  • Strength
  • Compositon
  • Treatment
    Non-small cell lung cancer (NSCLC) with  EGFR bearing mutations in the exon 20 region
  • Form
  • Brand
  • Quantity Unit
  • Manufacturer
    BIGBEAR Pharma,Laos PDR

Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.

Non-Small Cell Lung Cancer

Indicated for locally advanced or metastatic non–small cell lung cancer (NSCLC) in adults with epidermal growth factor receptor (EGFR) exon 20 insertion mutations and whose disease has progressed on or after platinum-based chemotherapy

160 mg PO qDay

Continue until disease progression or unacceptable toxicity

Dosage Modifications

Dose reductions for adverse reactions

  • First dose reduction: 120 mg PO qDay
  • Second dose reduction: 80 mg PO qDay

Black Box Warnings

QTc prolongation and torsades de pointes

  • Life-threatening heart rate–corrected QTc prolongation, including torsades de pointes, may occur
  • Monitor QTc and electrolytes periodically during treatment
  • Increase monitoring frequency in patients with risk factors for QTc prolongation (eg, congenital long QT syndrome, heart disease, electrolyte abnormalities)
  • Avoid coadministration with drugs that may further prolong the QTc interval (eg, drugs known to prolong QTc interval, strong or moderate CYP3A inhibitors)
  • Withhold, reduce dose, or permanently discontinue treatment based on the severity of QTc prolongation